Halozyme’s ENHANZE ® drug delivery technology, which is a proprietary, validated rHuPH20 enzyme paired with our unparalleled expertise in subcutaneous (SC) drug development, has been well-proven to enable rapid, high-volume subcutaneous delivery of co-administered drugs.

ENHANZE is based on Halozyme’s proprietary recombinant human hyaluronidase rHuPH20, which works locally and transiently to depolymerize hyaluronan (HA) in the extracellular matrix of the SC...

Here we found that depolymerization of the viscoelastic component of the interstitial matrix in animal models with a highly purified recombinant human hyaluronidase enzyme (rHuPH20) increased the dispersion of locally injected drugs, across a broad range of molecular weights without tissue distortion. rHuPH20 increased infusion rates and the pat...

With BaoPharma’s low-cost PH20 enzyme, clients no longer need to prioritize increasing antibody concentrations to reduce enzyme usage. This makes s.c. formulation more accessible, even for abs that can’t achieve high concentrations, effectively removing a key barrier.

2015年5月13日 · Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of subcutaneously delivered fluids and drugs. This report summarizes rHuPH20 immunogenicity findings from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab, rituximab, or insulin.

zyme (rHuPH20; Halozyme Therapeutics, Inc.) that fa-cilitates the SC delivery of co-administered therapeutics. rHuPH20 degrades the glycosaminoglycan hyaluronan, which plays a role in resistance to bulk fluid flow in the SC space, limiting large-volume SC drug delivery, disper-sion, and absorption. Co-administration with rHuPH20

2022年10月20日 · Hyaluronidase PH20 expression occurs primarily in adult testes. Low CD4+ T cell activation and B cell cross-reactivity by rHuPH20 suggest weak rHuPH20 immunogenicity potential. Restricted expression patterns of endogenous PH20 indicate low immunogenicity risk of subcutaneous rHuPH20.

Recombinant human hyaluronidase PH20 (rHuPH20) acts locally in the subcutaneous (SC) space to temporarily remove hyaluronan, thus facilitating the rapid SC delivery of large volumes of co-administered therapeutics. There is an extensive safety database for globally approved rHuPH20- containing products.

2012年4月27日 · rHuPH20-facilitated Ig infusion is associated with reduced local swelling and induration. The interstitial matrix, including glycosaminoglycans like hyaluronan, provides a barrier to bulk fluid flow and hinders the dispersion of SC administered fluids.

2021年7月22日 · Recombinant human hyaluronidase PH20 (rHuPH20) facilitates the dispersion and absorption of subcutaneously administered therapeutic agents. This study aimed to characterize the transient, local action of rHuPH20 in the subcutaneous (SC) space using focused biodistribution and dye dispersion studies conducted in mice.